

**Food and Drug Administration  
Center for Drug Evaluation and Research**

**Dermatologic and Ophthalmic Drugs Advisory Committee**

Holiday Inn  
8120 Wisconsin Avenue  
Bethesda, Maryland

**DRAFT Agenda**

**November 4-5, 2002**

- |       |   |   |
|-------|---|---|
| 8:30  | Call to Order and Opening Remarks   | Robert S. Stern, M.D.<br>Chair, DODAC                                 |
|       | Introduction of Committee   |   |
|       | Conflict of Interest Statement  | Karen M. Templeton-Somers, Ph.D.<br>Acting Executive Secretary, DODAC |
| 8:45  | Open Public Hearing   |   |
| 9:15  | Introduction  |   |
|       | Jonathan Wilkin, M.D., Director, Division of Dermatologic and Dental Drug Products, FDA |   |
| 9:20  | Presentations   |   |
| 10:15 | Questions to the Speakers   |   |
| 10:45 | Break   |   |
| 11:00 | Presentations   |   |
| 12:10 | Questions to the Speakers   |   |
| 12:30 | Lunch   |   |
| 1:30  | Presentations   |   |
| 3:15  | Break   |   |
| 3:30  | Questions to the Speakers   |   |
| 4:00  | Presentations   |   |
| 5:30  | Tentative Adjournment for the Day   |   |

## **November 5, 2002**

8:00	Call to Order and Opening Remarks	Robert S. Stern, M.D. Chair, DODAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Acting Executive Secretary, DODAC
8:15	Open Public Hearing	
8:45	Committee Discussion	
1:00	Tentative Adjournment	